1. 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC). (15th December 2019) Authors: Hidalgo, M; Semenisty, V; Bockorny, B; Borazanci, E; von Hoff, D D; Feliu, J; Sarvise, M Ponz; Abad, D Gutierrez; Peled, A; Bohana-Kashtan, O; Gozlan, Y; Sorani, E; Chaney, M; Kadosh, S; Vainstein, A V; Macarulla, T Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗